News

Article

AAO 2023: OTT166 progress: OcuTerra's diabetic retinopathy treatment

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, sat down with the Eye Care Network to share clinical updates at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Hi, I'm Kerrie Brady, the president and chief executive officer of OcuTerra Therapeutics. We're delighted to be here at AAO 2023 to catch up on all the latest of what's happening in our industry. We're particularly excited to be here so that we can share news of developments at OcuTerra.

Most importantly, in the middle of this year, we announced full enrollment in our Phase 2 DR:EAM Diabetic Retinopathy Early Active Management study with our OTT166, which is a novel, selective integrin inhibitor, which has been designed to be able to be delivered as an eye drop.

So, now with full enrollment and the Phase 2 DR:EAM study, we're on schedule to have our topline results in the first quarter of next year.

Thank you.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
© 2025 MJH Life Sciences

All rights reserved.